|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 1. The MMP inhibitor SB-3CT has differential effects on two guidance decisions
made by RGC axons. Lateral views of the brains and HRP-labelled optic
projections of stage 40 Xenopus embryos exposed at stage 33/34 to
either control media or to the MMP-specific inhibitor IV (SB-3CT). (A) Control
exposed brain. (B-D) Brains exposed to SB-3CT. At concentrations of 10 µM
(B) and 25 µM (C) axons extend, make the turn in the mid-diencephalon
(star), but are misguided at their target, the optic tectum. A demonstration
of the turning angle at the mid-diencephalon is shown in A and C. By contrast,
in GM6001-treated brains we found that axons failed to make the turn, and
instead grew towards the pineal gland
(Webber et al., 2002). (D)
With a higher concentration (50 µM) of the inhibitor, axon extension
defects are sometime seen. (E,F) A cyclic peptide MMP inhibitor, CTT, produces
a similar mistargeting phenotype (F), while a highly related inactive peptide,
STT, has no effect on the optic projection (E). The white dots indicate the
approximate anterior of the optic tectum (see Materials and methods). D,
dorsal; A, anterior; Tec, tectum; Tel, telencephalon; Di, diencephalon; Pi,
pineal gland; Hb, hindbrain. Scale bar: 50 µm.
|
